Anti-inflammatory

Atranorin
Catalog No: CFN98728

Atranorin shows significant antinociceptive and antiinflammatory activities, it has a relevant redox-active action, acting as a pro-oxidant or antioxidant agent depending on the radical, also, it will exert cytoprotective effects on cells under oxidative stress induced by H(2)O(2). Atranorin has suppression of viability and proliferation in tumour cell lines.

Artemetin
Catalog No: CFN98731

Artemetin has anti-inflammatory, antioxidant and antiapoptotic activities, it protects endothelial function through the activation of ERK1/2 and Akt. Intravenous injection of Artemetin (0.75 mg/kg) significantly reduces the hypertensive response to angiotensin I while increases the average length of bradykinin-induced hypotension.

Astragalin
Catalog No: CFN98733

Astragalin (kaempferol-3-O-glucoside) is a flavonoid with anti-inflammatory activity, it inhibits the TLR4-mediated NF-κB and mitogen-activated protein kinases signaling pathways. Astragalin ameliorates oxidative stress-associated epithelial eosinophilia and apoptosis through disturbing TLR4-PKCβ2-NADPH oxidase-responsive signaling; it also can be effective in allaying ROS-promoted bronchial fibrosis through inhibiting autophagosome formation in airways.

Taxifolin
Catalog No: CFN98734

Taxifolin exhibits important anti-tyrosinase activity, it also exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM.Taxifolin has anti-oxidant, anti-melanogenic, chemopreventive, anti-inflammatory, and cardioprotective effects. Taxifolin promotes osteoblast differentiation in MC3T3-E1 cells and also inhibit osteoclastogenesis in RAW264.7 cells, it also can enhance andrographolide-induced mitotic arrest and apoptosis in human prostate cancer cells via spindle assembly checkpoint activation.

Aromadendrin
Catalog No: CFN98736

Aromadendrin possesses anti-inflammatory, antioxidant, and anti-diabetic properties, it exhibits anti-inflammatory activity through the suppression of nuclear translocation of NF-κB and phosphorylation of JNK in LPS-stimulated RAW 264.7 macrophage cells. Aromadendrin treatment induces adipogenesis by increases in PPARγ2 expression, resulting in stimulation of glucose uptake and ameliorated insulin resistance, suggests that it may represent a potential therapeutic candidate for the management of type 2 DM. Aromadendrin has inhibitory activity on aldose reductase and the formation of advanced glycation end products.